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Acute coronary syndrome (ACS) is predominantly
caused by acute luminal narrowing due to sudden
thrombus formation or plaque haemorrhage imposed
on an atherosclerotic plaque [1]. A luminal throm-
bus forms as a direct consequence of plaque rupture
or erosion. The initial electrocardiogram can be
used to differentiate ST-elevation myocardial infarc-
tion (STEMI) and non-ST-elevation acute coronary
syndrome (NSTE-ACS). Patients with STEMI are char-
acterised by a complete and persistent occlusion of
a large epicardial coronary artery and are best man-
aged with immediate revascularisation by primary
percutaneous coronary intervention [2]. Primary per-
cutaneous coronary intervention (PCI) for STEMI is
associated with a reduction in mortality compared
with other reperfusion strategies [3].
In NSTE-ACS, typically an angiographically signifi-
cant stenosis is observedwhile epicardial flow is main-
tained. Therefore, multiple treatment strategies with
regard to coronary angiography and revascularisation
have been investigated over the years. The first step
is whether to proceed with a routine invasive or se-
lective invasive strategy. A routine invasive strategy
consists of angiography within 24 to 72 hours, while
a selective invasive strategy consists of coronary an-
giography only in cases of refractory angina and/or in-
ducible ischaemia by non-invasive stress testing. The
Dutch multicentre ICTUS (Invasive versus Conserva-
tive Treatment in Unstable coronary Syndromes) trial
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has demonstrated that both treatment strategies re-
sulted in comparable long-term death or myocardial
infarction [4]. A patient-pooled meta-analysis of three
trials showed that long-term rates of cardiovascular
death or myocardial infarction were lower with rou-
tine invasive strategy, and that the largest absolute
effect was seen in higher-risk patients [5]. The differ-
ence between the discrepant results can probably be
explained by the high angiography and revascularisa-
tion rates in the ICTUS trial. Current European guide-
lines recommend a routine invasive strategy for pa-
tients with intermediate-to-high-risk characteristics,
while the selective invasive strategy is reserved for
low-risk patients [6].
The second decision involves the optimal timing of
angiography after pursuing the routine invasive ap-
proach. Different timings are defined as immediate,
early invasive strategy (within 24hrs), or delayed in-
vasive strategy (after 24hrs). Several trials have inves-
tigated the immediate, or STEMI-like approach which
was not associated with improved outcomes [7–9].
A recent meta-analysis concluded that compared with
a delayed invasive strategy an early invasive strategy
does not reduce mortality in all patients with NSTE-
ACS [10]. However, an early invasive strategy might
reduce mortality in high-risk patients characterised
by a high Global Registry of Acute Coronary Events
(GRACE) risk score (above 140). For this reason, Eu-
ropean guidelines recommend angiography within
24 hours for high-risk patients, including transfer to
a PCI centre [6]. Based on multiple considerations,
including the availability of catheterisation laborato-
ries in the majority of Dutch cardiology departments
where coronary angiography is routinely performed
in NSTE-ACS patients, the Dutch ACS working group
does not consider referral within 24 hours as a pre-
requisite [11].
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In the current issue of the Netherlands Heart Jour-
nal, Badings et al. describe the use, timing and
outcome of coronary angiography in patients with
high-risk NSTE-ACS in daily clinical practice in the
Netherlands [12]. Consecutive ACS patients who pre-
sented at the Isala hospital in Zwolle are described.
In Zwolle, consecutive patients were enrolled in the
BAMI (Dutch abbreviation for ‘Treatment of Acute
Myocardial Ischaemia’) registry between 2006 and
2014. The main findings were as follows: 1) The
use of coronary angiography increased (from 77 to
90%); 2) There was a significant decrease in median
time to coronary angiography; 3) There was an in-
crease in patients undergoing early invasive strategy;
4) A higher GRACE risk score was associated with
a delayed invasive strategy; 5) No difference was ob-
served in mortality, reinfarction and bleeding event at
30-day follow-up between early and delayed invasive
strategy after adjustment for confounding factors.
The increased use of coronary angiography, de-
crease in the median time to coronary angiography
and increase of patients undergoing early invasive
strategy can probably be explained by the ESC guide-
line recommendations. This observation is in line
with a similar report from the Swedish SWEDEHEART
registry [13]. However, contrary to what might be
expected based on these recommendations, patients
with a higher baseline risk profile as indicated by the
GRACE risk score less frequently underwent an early
invasive strategy. This inverse relationship between
risk profile and the use of invasive treatment, the
treatment-risk paradox, has been described previ-
ously [13, 14]. The explanation for this treatment-
paradox is likely multifactorial [14]. Treating physi-
cians may fail to recognise high-risk clinical features
or to properly integrate them into overall risk stratifi-
cation. Moreover, physicians may be hesitant to rec-
ommend or perform invasive procedures for patients
at high risk for treatment complications. ‘Therapeutic
nihilism’ (belief that treatment might be ineffective in
patients with poor outcome) may also play a role. To
be noted, factors that are not routinely captured in
risk scores or studies, such as functional status, pa-
tient’s preference and frailty, do influence treatment
decisions in everyday practice.
Finally, even though higher-risk patients were
treated with a delayed invasive strategy, no differ-
ence was observed in clinical outcomes between an
early invasive strategy and a delayed invasive strat-
egy. A subgroup analysis showed that this finding
was consistent in patients with a GRACE score above
140. Although these results have to be interpreted in
the light of the limitations of a non-randomised com-
parison, the results are in line with previous Dutch
randomised studies regarding timing of coronary an-
giography/intervention in NSTE-ACS patients [15,
16]. In addition to the above-mentioned availabil-
ity of catheterisation laboratories in the majority of
Dutch cardiology departments, this important finding
might be explained by the correct identification of
true high-risk patients by the treating physician. In
the recently published Danish VERDICT trial, NSTE-
ACS patients were randomised to coronary angiog-
raphy within 12 hours or within 48 to 72 hours [17].
Although no differences in outcomes were observed,
there was a benefit of coronary angiography within
12 hours with regard to long-term outcomes in pa-
tients with a GRACE risk score above 140. The ques-
tion then arises whether high-risk NSTE-ACS patients
presenting to a cardiology department without coro-
nary angiography capabilities should be transferred
to a PCI-capable centre. We believe that a Dutch ran-
domised trial investigating these treatment strategies
in high-risk patients is needed, because the clinical
and logistical (ambulance and catheterisation facili-
ties/laboratories) implications of inter-facility transfer
are significant.
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